Other products in the same Health Canada class (C10A, C10AB) — coverage varies; not interchangeable
Bezafibrate (Bezalip): general benefit
Gemfibrozil (Lopid): general benefit, Not a benefit
Clofibrate (Atromid-S): not a benefit
Atorvastatin (Lipitor): general benefit
Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
Colesevelam (Lodalis): general benefit, Listing status unconfirmed
9 more in the class list below
Lipidil EZ · DIN 02269074 · 48mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lipidil EZ (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lipidil EZ · DIN 02269074
Manufacturer: Fournier Pharma Inc.; listing date 2006-10-23
Health Canada: Marketed since 2016-04-12 · brand LIPIDIL EZ · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 48 MG · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75447 · Verify on the e-Formulary ↗ (DIN 02269074)
Source record
DIN 02269074: Lipidil EZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600054; group id 303; item number 0662; lccId None; manufacturer id FOU
Source form: Tab; strength: 48mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.5096; ministry $0.3560
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02269074
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75447Interchangeable products
Sandoz Fenofibrate E · DIN 02390698 · $0.3560
Shortage status: resolved shortage (ended 2023-11-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02269074
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Fenofibrate E · DIN 02390698 · 48mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Fenofibrate E · DIN 02390698
Manufacturer: Sandoz Canada Inc.; listing date 2013-03-20
Health Canada: Marketed since 2012-12-12 · brand SANDOZ FENOFIBRATE E · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 48.0 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Fenofibrate E: Formulary list price $0.3560/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87610 · Verify on the e-Formulary ↗ (DIN 02390698)
Source record
DIN 02390698: Sandoz Fenofibrate E
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600054; group id 303; item number 0662; lccId None; manufacturer id SDZ
Source form: Tab; strength: 48mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3560; ministry $0.3560
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390698
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87610Interchangeable products
Lipidil EZ · DIN 02269074 · $0.3560
Shortage status: resolved shortage (ended 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390698
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lipidil EZ · DIN 02269082 · 145mg · tablet
General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lipidil EZ (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lipidil EZ · DIN 02269082
Manufacturer: Fournier Pharma Inc.; listing date 2006-10-23
Health Canada: Marketed since 2015-04-01 · brand LIPIDIL EZ · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 145 MG · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75448 · Verify on the e-Formulary ↗ (DIN 02269082)
Source record
DIN 02269082: Lipidil EZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600055; group id 303; item number 0663; lccId None; manufacturer id FOU
Source form: Tab; strength: 145mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3048; ministry $0.5489
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02269082
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75448Interchangeable products
Sandoz Fenofibrate E · DIN 02390701 · $0.5489
Taro-Fenofibrate E · DIN 02454696 · $0.5489
Shortage status: resolved shortage (ended 2025-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02269082
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Fenofibrate E · DIN 02390701 · 145mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Fenofibrate E · DIN 02390701
Manufacturer: Sandoz Canada Inc.; listing date 2012-10-30
Health Canada: Marketed since 2012-08-24 · brand SANDOZ FENOFIBRATE E · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 145.0 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Fenofibrate E: Formulary list price $0.5489/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5489 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87611 · Verify on the e-Formulary ↗ (DIN 02390701)
Source record
DIN 02390701: Sandoz Fenofibrate E
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600055; group id 303; item number 0663; lccId None; manufacturer id SDZ
Source form: Tab; strength: 145mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.5489; ministry $0.5489
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390701
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87611Interchangeable products
Lipidil EZ · DIN 02269082 · $0.5489
Taro-Fenofibrate E · DIN 02454696 · $0.5489
Shortage status: resolved shortage (ended 2025-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390701
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Fenofibrate E · DIN 02454696 · 145mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Fenofibrate E · DIN 02454696
Manufacturer: Sun Pharma; listing date 2021-01-29
Health Canada: Marketed since 2025-11-07 · brand SPC-FENOFIBRATE E · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 145 MG · company Sun pharma canada inc · schedule Prescription
Taro-Fenofibrate E: Formulary list price $0.5489/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5489 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94139 · Verify on the e-Formulary ↗ (DIN 02454696)
Source record
DIN 02454696: Taro-Fenofibrate E
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600055; group id 303; item number 0663; lccId None; manufacturer id SPC
Source form: Tab; strength: 145mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.5489; ministry $0.5489
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454696
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94139Interchangeable products
Lipidil EZ · DIN 02269082 · $0.5489
Sandoz Fenofibrate E · DIN 02390701 · $0.5489
Shortage status: active shortage (reported 2026-09-03, estimated to end 2026-09-11, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454696
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Feno-Super · DIN 02246860 · 160mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Feno-Super · DIN 02246860
Manufacturer: A A Pharma Inc.; listing date 2006-06-14
Health Canada: Marketed since 2021-09-24 · brand AA-FENO-SUPER · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 160 MG · company Aa pharma inc · schedule Prescription
AA-Feno-Super: Formulary list price $1.0022/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0022 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71083 · Verify on the e-Formulary ↗ (DIN 02246860)
Source record
DIN 02246860: AA-Feno-Super
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600043; group id 303; item number 0661; lccId None; manufacturer id AAP
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0022; ministry $1.0022
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246860
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71083Interchangeable products
Lipidil Supra · DIN 02241602 · $1.0022
Shortage status: resolved shortage (ended 2024-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246860
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lipidil Supra · DIN 02241602 · 160mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lipidil Supra (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lipidil Supra · DIN 02241602
Manufacturer: BGP Pharma ULC; listing date 2001-06-07
Health Canada: Marketed since 2016-03-08 · brand LIPIDIL SUPRA · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 160 MG · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65259 · Verify on the e-Formulary ↗ (DIN 02241602)
Source record
DIN 02241602: Lipidil Supra
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600043; group id 303; item number 0661; lccId None; manufacturer id BGP
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4832; ministry $1.0022
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241602
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65259Interchangeable products
AA-Feno-Super · DIN 02246860 · $1.0022
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241602
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Feno-Micro · DIN 02239864 · 200mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Feno-Micro · DIN 02239864
Manufacturer: A A Pharma Inc.; listing date 2000-01-17
Health Canada: Marketed since 2020-01-21 · brand AA-FENO-MICRO · ATC C10AB05 FENOFIBRATE · form Capsule · route Oral · ingredients FENOFIBRATE 200 MG · company Aa pharma inc · schedule Prescription
AA-Feno-Micro: Formulary list price $0.9257/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9257 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63352 · Verify on the e-Formulary ↗ (DIN 02239864)
Source record
DIN 02239864: AA-Feno-Micro
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600030; group id 303; item number 0659; lccId None; manufacturer id AAP
Source form: Cap; strength: 200mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.9257; ministry $0.9257
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239864
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63352Interchangeable products
Lipidil Micro · DIN 02146959 · not recorded
Shortage status: resolved shortage (ended 2021-08-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239864
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Feno-Micro · DIN 02243180 · 67mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Feno-Micro · DIN 02243180
Manufacturer: A A Pharma Inc.; listing date 2008-01-15
Health Canada: Marketed since 2019-11-15 · brand AA-FENO-MICRO · ATC C10AB05 FENOFIBRATE · form Capsule · route Oral · ingredients FENOFIBRATE 67 MG · company Aa pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67060 · Verify on the e-Formulary ↗ (DIN 02243180)
Source record
DIN 02243180: AA-Feno-Micro
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240600067; group id 303; item number 0658; lccId None; manufacturer id AAP
Source form: Cap; strength: 67mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.6025; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243180
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67060Interchangeable products
Lipidil Micro · DIN 02230283 · not recorded
Shortage status: resolved shortage (ended 2022-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243180
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Feno-Super · DIN 02246859 · 100mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Feno-Super · DIN 02246859
Manufacturer: A A Pharma Inc.; listing date 2008-12-03
Health Canada: Marketed since 2021-09-24 · brand AA-FENO-SUPER · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 100 MG · company Aa pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71082 · Verify on the e-Formulary ↗ (DIN 02246859)
Source record
DIN 02246859: AA-Feno-Super
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240600046; group id 303; item number 0660; lccId None; manufacturer id AAP
Source form: Tab; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.9883; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246859
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71082Interchangeable products
Lipidil Supra · DIN 02241601 · not recorded
Sandoz Fenofibrate S · DIN 02288044 · not recorded
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-16, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246859
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Fenofibrate: Formulary list price $0.6105/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6105 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43440 · Verify on the e-Formulary ↗ (DIN 02225980)
Source record
DIN 02225980: Apo-Fenofibrate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600018; group id 303; item number 0657; lccId None; manufacturer id APX
Source form: Cap; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.6105; ministry $0.6105
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225980
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43440Interchangeable products
Lipidil · DIN 00885827 · not recorded
Shortage status: resolved shortage (ended 2018-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02225980
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2022-01-05 — choose a marketed DIN from the same-category list.
Lipidil Micro · DIN 02230283 · 67mg · capsule
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-21 — choose a marketed DIN from the same-category list.Discontinued 2003-07-21 · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-07-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lipidil Micro · DIN 02230283
Manufacturer: Fournier Pharma Inc.; listing date 2008-01-15
Health Canada: Cancelled post market since 2003-07-21 · brand LIPIDIL MICRO - CAP 67MG · ATC C10AB05 FENOFIBRATE · form Capsule · route Oral · ingredients FENOFIBRATE 67 MG/CAP · company Laboratoires fournier s.a.s. · schedule Prescription
Lipidil Micro: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49040 · Verify on the e-Formulary ↗ (DIN 02230283)
Source record
DIN 02230283: Lipidil Micro
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240600067; group id 303; item number 0658; lccId None; manufacturer id FOU
Source form: Cap; strength: 67mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230283
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49040Interchangeable products
AA-Feno-Micro · DIN 02243180 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230283
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-07-21 — choose a marketed DIN from the same-category list.
Lipidil · DIN 00885827 · 100mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-08-11 — choose a marketed DIN from the same-category list.Discontinued 1997-08-11 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-08-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1997-08-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lipidil · DIN 00885827
Manufacturer: Jouveinal Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1997-08-11 · brand LIPIDIL CAP 100MG · ATC C10AB05 FENOFIBRATE · form Capsule · route Oral · ingredients FENOFIBRATE 100 MG/CAP · company Laboratoires fournier s.a.s. · schedule Prescription
Lipidil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10835 · Verify on the e-Formulary ↗ (DIN 00885827)
Source record
DIN 00885827: Lipidil
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240600018; group id 303; item number 0657; lccId None; manufacturer id JOU
Source form: Cap; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00885827
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10835Interchangeable products
Apo-Fenofibrate · DIN 02225980 · $0.6105
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00885827
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1997-08-11 — choose a marketed DIN from the same-category list.
Lipidil Supra · DIN 02241601 · 100mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-01-29 — choose a marketed DIN from the same-category list.Discontinued 2014-01-29 · checked 2026-09-18
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-01-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-01-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
Savings card: RxHelp ONE lists Lipidil Supra (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lipidil Supra · DIN 02241601
Manufacturer: Laboratoires Fournier S.A.; listing date 2008-11-04
Health Canada: Cancelled post market since 2014-01-29 · brand LIPIDIL SUPRA 100 MG · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 100 MG · company Laboratoires fournier s.a.s. · schedule Prescription
Lipidil Supra: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65258 · Verify on the e-Formulary ↗ (DIN 02241601)
Source record
DIN 02241601: Lipidil Supra
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240600046; group id 303; item number 0660; lccId None; manufacturer id LAF
Source form: Tab; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241601
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65258Interchangeable products
AA-Feno-Super · DIN 02246859 · not recorded
Sandoz Fenofibrate S · DIN 02288044 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241601
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-01-29 — choose a marketed DIN from the same-category list.
Sandoz Fenofibrate S · DIN 02288044 · 100mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.Discontinued 2020-12-31 · checked 2026-09-18
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Fenofibrate S · DIN 02288044
Manufacturer: Sandoz Canada Inc.; listing date 2009-08-18
Health Canada: Cancelled post market since 2020-12-31 · brand SANDOZ FENOFIBRATE S · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 100 MG · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77343 · Verify on the e-Formulary ↗ (DIN 02288044)
Source record
DIN 02288044: Sandoz Fenofibrate S
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240600046; group id 303; item number 0660; lccId None; manufacturer id SDZ
Source form: Tab; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7874; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02288044
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77343Interchangeable products
AA-Feno-Super · DIN 02246859 · not recorded
Lipidil Supra · DIN 02241601 · not recorded
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02288044
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Lipidil Micro · DIN 02146959 · 200mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-11-09 — choose a marketed DIN from the same-category list.Discontinued 2016-11-09 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-11-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-11-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lipidil Micro · DIN 02146959
Manufacturer: Solvay Pharma Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2016-11-09 · brand LIPIDIL MICRO · ATC C10AB05 FENOFIBRATE · form Capsule · route Oral · ingredients FENOFIBRATE 200 MG · company American biotech labs · schedule Prescription
Lipidil Micro: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17849 · Verify on the e-Formulary ↗ (DIN 02146959)
Source record
DIN 02146959: Lipidil Micro
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240600030; group id 303; item number 0659; lccId None; manufacturer id SPH
Source form: Cap; strength: 200mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02146959
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17849Interchangeable products
AA-Feno-Micro · DIN 02239864 · $0.9257
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146959
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-11-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered
Matched class: 24:06 Antilipemic Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM
Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN
24:00 CARDIOVASCULAR DRUGS
· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06
and 4 more
INDICATIONS AND CLINICAL USE
FENOFIBRATE (fenofibrate, non-micronized formulation) and AA-FENO-MICRO
(fenofibrate, micronized formulation) are indicated as an adjunct to diet and other therapeutic
measures for:
Page 3 of 37
1) Treatment of patients with hypercholesterolemia, Fredrickson classification Types IIa and
IIb mixed hyperlipidemias, to regulate lipid levels (reduce serum triglycerides and LDL
cholesterol levels and increase HDL cholesterol).
2) Treatment of adult patients with very high serum triglyceride levels, Fredrickson
classification Type IV and Type V hyperlipidemias, who are at a high risk of sequelae and
complications (i.e., pancreatitis) from their hyperlipidemia.
FENOFIBRATE and AA-FENO-MICRO alone may not be adequate therapy in some patients
with familial combined hyperlipidemia with Type IIb and Type IV hyperlipoproteinemia.
Initial therapy for hyperlipidemia should include a specific diet (at least equivalent to the
American Heart Association (AHA) Step I diet), weight reduction, and…
https://pdf.hres.ca/dpd_pm/00053567.PDF
PM date: not printed or not captured
Source product: AA-FENO-MICRO; DIN 02239864; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Taro-Fenofibrate E · DIN 02454696
Shortage status: active shortage (reported 2026-09-03, estimated to end 2026-09-11, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454696
AA-Feno-Super · DIN 02246859
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-16, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246859
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For AA-Feno-Micro, AA-Feno-Super, Lipidil Micro, Lipidil, Lipidil Supra, Sandoz Fenofibrate S: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.